ProfessionalsBonnie Chen
Tel: +1-212-373-3905
Fax: +1-212-492-0905
bchen@paulweiss.com
1285 Avenue of the Americas
New York,
NY
10019-6064
Fax: +1-212-492-0905
Bonnie Chen is a partner in the Corporate Department and a member of the Intellectual Property & Technology Transactions Group. Bonnie focuses her practice on advising clients on a wide range of IP and technology-related corporate and commercial transactions, including intellectual property aspects of public and private mergers, acquisitions, joint ventures, and carve-outs. She also advises on licensing and collaboration agreements, research and development agreements, supply agreements, distribution agreements and other strategic commercial agreements.
With a degree in biological engineering, Bonnie has extensive experience with advising clients in the pharmaceutical, biotechnology and medical device industries, including transactions involving small molecules, biologics, and gene therapies. Bonnie also has extensive experience with advising clients in the technology, media and telecommunications, financial institutions, retail and fashion industries.
In 2024, Bonnie was named as part of the “IP Team of the Year” by Luxury Law, was shortlisted as an “Intellectual Property Rising Star" by Euromoney’s 2024 Women in Business Law Americas Awards and recognized as a "500 X – The Next Generation" lawyer by Lawdragon.
EXPERIENCE
Bonnie’s notable representations have included:
- GSK in its acquisition of CMG1A46, an autoimmune disease treatment, from Chimagen Biosciences
- Carrier Global Corporation in its:
- $3 billion sale of its commercial and residential fire business to an affiliate of Lone Star Funds
- €12 billion acquisition of Viessmann Climate Solution
- $4.95 billion sale of its global access solutions business to Honeywell
- $1.425 billion sale of its industrial fire business to Sentinel Capital Partners
- $775 million sale of its global commercial refrigeration business to Haier
- Merck in its $10.8 billion acquisition of Prometheus Biosciences
- The Estée Lauder Companies in its $2.8 billion acquisition of the Tom Ford brand
- Funds managed by affiliates of Apollo Global Management in:
- an investment of $11 billion to acquire from Intel Corporation a 49% equity interest in a joint venture entity related to Intel’s Fab 34
- their ¥311 billion investment (approximately $2.05 billion) to acquire a majority stake in Panasonic Automotive Systems Co.
- Rodina Capital in its acquisition of Rubicon Technologies’ fleet technology business unit and convertible preferred equity
- General Electric in its spin-off of its renewable energy and power businesses and launch of GE Vernova
- AbbVie in its up to $212.5 million acquisition of Landos Biopharma
- IBM in its acquisition of NS1
Prior to joining Paul, Weiss, Bonnie’s various high-profile transactions include advising:
- Roche in its acquisitions of Flatiron Health and Tensha Therapeutics
- Bristol Myers Squibb in its acquisition of Forbius
- L Brands in its separation from Victoria’s Secret
- The Ferrero Group’s in its acquisition of Kellogg Company’s cookie, fruit and fruit-flavored snack, ice cream cone and pie crust businesses
- Novartis in its acquisition of worldwide rights for Fibroblast Activation Protein targeting agents from iTheranostics (an affiliate of SOFIE Biosciences)
- Comcast in its “put/call” agreement with The Walt Disney Company regarding NBCUniversal’s 33% ownership interest in Hulu
- AstraZeneca in its acquisition of ZS Pharma
- F. Corporation in its sale of its Contemporary Brands businesses to Delta Galil Industries
- Solvay in its buyout of its joint venture with Eastman Chemical Company
- Novo Nordisk in its acquisition of Emisphere Technologies
- Shire in its sale of its mRNA platform to Translate Bio and sale of its oncology business to Servier
- Roivant Sciences in its combination with a SPAC
- AC Immune in its collaboration with Eli Lilly
- BVF Partners LP in MoonLake Immunotherapeutics’ exclusive in-license of Sonelokimab from Merck KGaA
- Freeline Therapeutics in its commercial manufacturing arrangement with Brammer Bio
- AC Immune, ADC Therapeutics and Freeline Therapeutics in their IPOs
- The underwriters for Editas Medicine, Prime Medicine, Zai Labs and Denali Therapeutics in their IPOs